title: Experimental evaluation of coronary thrombodynamics and effects of pharmacological interventions in acute coronary syndromes.
abstract: Intracoronary thrombodynamics in acute coronary syndromes was studied with an experimental canine model. An intracoronary thrombus was precipitated at the mock ruptured atheromatous plaque consisting of cholesterol and collagen. In 8 of 10 control models, acute myocardial infarction (AMI) was induced by intracoronary occlusive thrombus 1 h after the start of the experiment. Coronary blood flow decreased continuously (Type A, n = 5) or cyclically (Type B, n = 3) to end in AMI. Effects of pharmacological interventions to prevent AMI were also studied with the model. An intravenous bolus injection of a thromboxane synthetase inhibitor (RS-5186), heparin, a thrombin inhibitor (argatroban), and a thrombolytic agent (urokinase) was performed in 10 models for each drug. The incidence of AMI was significantly decreased to 3 of the 10 models injected with the thromboxane synthetase inhibitor and heparin (p < .05, each drug group vs. control). The preventive effect of argatroban was more potent and AMI occurred in 2 of 10 models (p < 0.01, argatroban vs control).
authors.affiliation: Department of Cardiology, Tokai University, Kanagawa, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tomoda
mesh_terms: D000818:Animals; D000991:Antithrombins / Q000008:administration & dosage / Q000494:pharmacology; D001120:Arginine / Q000031:analogs & derivatives; D003326:Coronary Circulation / Q000187:drug effects; D003328:Coronary Thrombosis / Q000150:complications; D004285:Dogs; D006493:Heparin / Q000008:administration & dosage* / Q000494:pharmacology; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D010875:Pipecolic Acids / Q000008:administration & dosage / Q000494:pharmacology; D013449:Sulfonamides; D013876:Thiophenes / Q000008:administration & dosage* / Q000494:pharmacology; D015912:Thrombolytic Therapy; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000991:Antithrombins; D010875:Pipecolic Acids; D013449:Sulfonamides; D013876:Thiophenes; C055806:RS 5186; D006493:Heparin; D001120:Arginine; D014568:Urokinase-Type Plasminogen Activator; D013930:Thromboxane-A Synthase; C031942:argatroban